Antivirals
| | | | Table 7-2 Oral Antiviral Drugs | | Name | | Mechanism of Action | | Spectrum, Pregnancy Category | | Miscellaneous | | Acyclovir | | Phosphorylated by viral thymidine kinase to acyclovir monophosphate, which blocks viral DNA polymerase → stops viral DNA synthesis | | Herpes simplex virus (HSV), varicella- zoster virus (VZV)
Pregnancy category B | | SE: IV infusion associated with reversible obstructive nephropathy, rarely may see severe CNS Pregnancy category B changes (i.e., seizures) | | Valacyclovir | | Prodrug of acyclovir, same mechanism of action (viral thymidine kinase-dependent activity) | | HSV, VZV, cytomegalovirus (CMV)
Category B | | Better bioavailability than acyclovir
SE: TTP/HUS* seen in advanced HIV disease and transplant patients taking high doses | | Penciclovir | | Phosphorylated by viral thymidine kinase (similar mechanism to acyclovir) | | HSV, VZV | | Low bioavailability so typically used in topical form | | Famciclovir | | Prodrug of penciclovir with same mechanism as above | | HSV, VZV
Category B | | Better bioavailability than Category B penciclovir | | Ganciclovir | | Phosphorylated by viral thymidine kinase; same mechanism as above | | CMV (retinitis)
Category C | | Better activity against CMV than acyclovir; ↓ oral bioavailability
SE: neutropenia, bone marrow suppression, mucositis, thrombocytopenia, seizures hepatic dysfunction | | Foscarnet | | Noncompetitive inhibition of viral DNA polymerases; analogue of pyrophosphate
Does not require phosphorylation so active against acyclovir-resistant viruses | | CMV (retinitis), resistant HSV, resistant VZV
Category C | | Only IV form; active against infections resistant to acyclovir, famciclovir, ganciclovir
SE: penile ulcerations or erosions, nephrotoxicity | | Cidofovir | | Nucleoside analogue, inhibits viral DNA polymerase, independent of thymidine kinase activation | | CMV
Category C | | IV only; active against infections resistant to ganciclovir/foscarnet
SE: renal proteinuria, renal toxicity, ↑ creatinine | | Amantidine, Rimantidine | | Inhibit uncoating of viral DNA within infected host cells (prevents replication) | | Influenza A/C, rubella
Category C | | SE: anticholinergic symptoms, Category C ataxia, and photosensitivity | | | | | | | | | | | | | | | | | | *TTP: thrombotic thrombocytopenic purpura HUS: hemolytic uremic syndrome |
| | | | |
|
| | | | Table 7-3 Antiretroviral Drugs | | Name | | Mechanism of Action | | Characteristics | Nucleoside/nucleotide reverse transcriptase inhibitors | | Zidovudine (AZT) | | Thymidine analogue, inhibits HIV reverse transcriptase (RT) | | SE: melanonychia, mucocutaneous pigmentation, bone marrow suppression, lipodystrophy
Pregnancy category C | | Didanosine (ddI) | | Pyrimidine analogue, similar to AZT | | SE: pancreatitis, optic neuritis, peripheral neuropathy, lactic acidosis; pregnancy category B | | Abacavir (ABC) | | Nucleoside RT inhibitor | | SE: hypersensitivity reaction (can be fatal upon rechallenge)
Pregnancy category C | | Tenofovir | | Nucleotide analogue, inhibits RT | | Peripheral wasting, cushingoid appearance Pregnancy category B | Protease inhibitors | | Indinavir, Ritonavir, Lopinavir | | Block HIV-1 protease enzymes | | SE: lipodystrophy (buffalo hump), gynecomastia, periungual pyogenic granulomas, paronychia, hepatotoxicity | | | | | | |
| | | | |
|
|